<DOC>
	<DOCNO>NCT00689052</DOCNO>
	<brief_summary>The primary objective study assess efficacy safety extended-release ( ER ) formulation pramipexole comparison placebo treatment fibromyalgia . The objective open-label phase ass safety profile effect Pramipexole ( PPX ) extended-release ( ER ) fibromyalgia patient 24-week period .</brief_summary>
	<brief_title>Pramipexole ER v . Placebo Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Male female outpatient great equal 18 year age 2 . Meet criterion primary fibromyalgia define American College Rheumatology ( ACR ) : widespread ache pain four quadrant body axial skeleton great 3 month duration great equal 11 18 tender point digital palpitation examination approximate force 4 kilogram per centimeter square ( kg/cm2 ) 3 . Pain score great equal 4 ( score screen weekly mean baseline ) 11point Likert pain scale 0 = pain 10 = worst possible pain 4 . Score great equal 4 ( = moderately ill ) Clinical Global Impression Severity ( CGIS ) screen baseline 5 . All female childbearing potential must test negative pregnancy Visit 1 . Females childbearing potential ( surgically sterilize menarche two year postmenopausal ) must agree utilize medically acceptable reliable mean birth control determine investigator study one month follow last dose study medication . Examples reliable method include : use hormonal contraception ( oral , injectable , subcutaneous ) , doublebarrier method , abstinence , partner vasectomy , hormonal intrauterine device 6 . Educational level degree understand patient communicate intelligibly investigator study coordinator 7 . Judged reliable agree keep appointment clinic visit , test , procedure require protocol 1 . Employees Boehringer Ingelheim ( BI ) ( , employee , temporary contract worker , designees responsible conduct study ) 2 . Have receive treatment within 30 day prior screen drug receive regulatory approval indication 3 . Have previously complete withdrawn study study investigate pramipexole . 4 . Any current previous diagnosis psychosis , bipolar disorder , schizoaffective disorder assess Mini International Neuropsychiatric Interview ( MINI ) 5 . Have primary anxiety disorder within past year assess Mini International Neuropsychiatric Interview ( MINI ) 6 . Have Diagnosis Statistical Manual Mental Diseases , 4th Edition ( DSMIV ) Axis II disorder would interfere protocol compliance 7 . Medium high risk suicidality assess Mini International Neuropsychiatric Interview ( MINI ) 8 . History substance abuse/dependence within past year , exclude nicotine caffeine 9 . A positive urine drug screen substance abuse exclude medication 10 . Women pregnant breastfeed 11 . Have pain symptom relate traumatic injury interfere interpretation outcome measure 12 . Patients regional pain syndrome , multiple surgery fail back surgery syndrome 13 . A confirmed previous diagnosis rheumatoid arthritis , inflammatory arthritis , infectious arthritis , autoimmune disease 14 . Abnormal CReactive Protein , AntiNuclear Antibody ( ANA ) , Rheumatoid factor , Thyroid Stimulating Hormone ( TSH ) 15 . Any serious unstable medical psychiatric condition clinically significant abnormality labs screen would lead hospitalization course study otherwise compromise study participation 16 . Have uncontrolled seizure 17 . Taking prohibited medication discontinue screen 18 . Patients treatmentrefractory whose response may compromise disability compensation issue 19 . Patients frequent severe allergic reaction multiple medication 20 . Prior current treatment pramipexole 21 . Clinically significant renal disease 22 . Current previous diagnosis malignant melanoma 23 . Clinically relevant ophthalmopathy 24 . Documented sleep apnea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>